Abstract
Guselkumab appears to be safe and effective in the treatment of patients with HS, who do not respond to adalimumab and other systemic therapies. Guselkumab can be used in patients with comorbid Crohn's disease.
Author supplied keywords
Cite
CITATION STYLE
APA
Jørgensen, A. H. R., Holm, J. G., & Thomsen, S. F. (2020). Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety. Clinical Case Reports, 8(12), 2874–2877. https://doi.org/10.1002/ccr3.3090
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free